BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis
Authors
Keywords
Mutation detection, Colorectal cancer, Mutation, Cancer treatment, Dideoxy DNA sequencing, Polymerase chain reaction, Human genetics, Prognosis
Journal
PLoS One
Volume 11, Issue 3, Pages e0151865
Publisher
Public Library of Science (PLoS)
Online
2016-03-19
DOI
10.1371/journal.pone.0151865
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial
- (2015) N. Normanno et al. ANNALS OF ONCOLOGY
- Elucidating the prognostic significance ofKRAS,NRAS,BRAFandPIK3CAmutations in Chinese patients with metastatic colorectal cancer
- (2015) Brigette B Ma et al. Asia-Pacific Journal of Clinical Oncology
- A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer
- (2015) Akihito Kawazoe et al. BMC CANCER
- Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
- (2015) Sally Temraz et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- HER2/neu testing in primary colorectal carcinoma
- (2014) B Ingold Heppner et al. BRITISH JOURNAL OF CANCER
- Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
- (2014) Simonetta M. Leto et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Differential Features of Microsatellite-Unstable Colorectal Carcinomas Depending on EPCAM Expression Status
- (2014) Jung Ho Kim et al. Korean Journal of Pathology
- Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review
- (2014) Yu Imamura et al. Molecular Cancer
- HER2 Status in Colorectal Cancer: Its Clinical Significance and the Relationship between HER2 Gene Amplification and Expression
- (2014) An Na Seo et al. PLoS One
- Clinical meaning ofBRAFmutation in Korean patients with advanced colorectal cancer
- (2014) Bun Kim WORLD JOURNAL OF GASTROENTEROLOGY
- Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution
- (2014) S. Misale et al. Cancer Discovery
- HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients
- (2013) V Martin et al. BRITISH JOURNAL OF CANCER
- A systematic review of dual targeting in HER2-positive breast cancer
- (2013) Iben Kümler et al. CANCER TREATMENT REVIEWS
- Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis
- (2013) Jens Neumann et al. VIRCHOWS ARCHIV
- Rare Though Not Mutually Exclusive: A Report of Three Cases of Concomitant KRAS and BRAF Mutation and a Review of the Literature
- (2013) Ibrahim Halil Sahin et al. Journal of Cancer
- Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?
- (2012) Tomoya Yokota Anti-Cancer Agents in Medicinal Chemistry
- Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
- (2012) Mi-Jung Kim et al. BMC CANCER
- Microsatellite instability testing in Korean patients with colorectal cancer
- (2012) Jung Ryul Oh et al. Familial Cancer
- PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
- (2011) C. Mao et al. ANNALS OF ONCOLOGY
- Targeting PI3K Signaling as a Therapeutic Approach for Colorectal Cancer
- (2011) Jing Zhang et al. GASTROENTEROLOGY
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- BRAFV600E: Implications for Carcinogenesis and Molecular Therapy
- (2011) E. R. Cantwell-Dorris et al. MOLECULAR CANCER THERAPEUTICS
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
- (2011) K. Yonesaka et al. Science Translational Medicine
- Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma
- (2011) Sung Lee et al. VIRCHOWS ARCHIV
- Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
- (2010) S. E. Baldus et al. CLINICAL CANCER RESEARCH
- The PI3K Pathway As Drug Target in Human Cancer
- (2010) Kevin D. Courtney et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program
- (2008) J. H. J. M. van Krieken et al. VIRCHOWS ARCHIV
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started